U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07759856) titled 'NK Cells Plus ICI for SCLC Maintenance' on Aug. 02.
Brief Summary: This research study is designed for patients with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard chemotherapy, with at least two cycles combined with immunotherapy, and have achieved disease control (stable disease, partial response, or complete response) at their last efficacy evaluation.
In this study, participants will be randomly assigned to one of two groups:
Group A will receive standard immunotherapy plus 1 to 3 courses of allogeneic natural killer (NK) cell therapy. Each course consists of six NK cell infu...